BACKGROUND: The safety of H1N1 vaccine is unknown in egg allergic (EA) recipients. OBJECTIVES: To establish the safety of administering H1N1 vaccine and to evaluate the predictability of H1N1 skin testing in EA patients. METHODS: In a controlled, prospective trial, H1N1 skin testing and vaccination was compared between EA patients (n = 105) and non-EA controls (n = 19). Those with negative H1N1 skin test results received a full H1N1 dose; those with a positive skin test result received a graded challenge (10%, 90%). Booster vaccine, if required, was given as a single dose from a different lot without prior testing. RESULTS: Prick and intradermal test results were positive in 3 (2.4%) of 124 and 41 (33.1%) of 124 study participants, respectively. Forty-one individuals received a 2-step graded vaccine challenge, including 13 of 25 with a history of egg anaphylaxis. No significant allergic reactions resulted from either method of vaccination or from subsequent booster doses. CONCLUSION: All study participants received the H1N1 vaccine without significant allergic reactions. Skin testing is unnecessary and does not predict vaccine tolerance. All study participants who received a graded challenge tolerated a single dose booster from a different, untested lot, including 7 individuals with a history of egg-induced anaphylaxis. We recommend administration of H1N1 vaccine to EA children without prior skin testing or graded challenge dosing.
BACKGROUND: The safety of H1N1 vaccine is unknown in egg allergic (EA) recipients. OBJECTIVES: To establish the safety of administering H1N1 vaccine and to evaluate the predictability of H1N1 skin testing in EA patients. METHODS: In a controlled, prospective trial, H1N1 skin testing and vaccination was compared between EA patients (n = 105) and non-EA controls (n = 19). Those with negative H1N1 skin test results received a full H1N1 dose; those with a positive skin test result received a graded challenge (10%, 90%). Booster vaccine, if required, was given as a single dose from a different lot without prior testing. RESULTS: Prick and intradermal test results were positive in 3 (2.4%) of 124 and 41 (33.1%) of 124 study participants, respectively. Forty-one individuals received a 2-step graded vaccine challenge, including 13 of 25 with a history of egg anaphylaxis. No significant allergic reactions resulted from either method of vaccination or from subsequent booster doses. CONCLUSION: All study participants received the H1N1 vaccine without significant allergic reactions. Skin testing is unnecessary and does not predict vaccine tolerance. All study participants who received a graded challenge tolerated a single dose booster from a different, untested lot, including 7 individuals with a history of egg-induced anaphylaxis. We recommend administration of H1N1 vaccine to EA children without prior skin testing or graded challenge dosing.
Authors: Julia Elizabeth Mainwaring Upton; David Brian Hummel; Anna Kasprzak; Adelle Roberta Atkinson Journal: Allergy Asthma Clin Immunol Date: 2012-03-02 Impact factor: 3.406
Authors: Cosby A Stone; Christine R F Rukasin; Thomas M Beachkofsky; Elizabeth J Phillips Journal: Br J Clin Pharmacol Date: 2019-11-05 Impact factor: 4.335
Authors: Luke Webb; Maureen Petersen; Stephen Boden; Virginia LaBelle; J Andrew Bird; Druhan Howell; A Wesley Burks; Susan Laubach Journal: J Allergy Clin Immunol Date: 2011-04-02 Impact factor: 10.793
Authors: Fabrizio Franceschini; Paolo Bottau; Silvia Caimmi; Giuseppe Crisafulli; Liotti Lucia; Diego Peroni; Francesca Saretta; Mario Vernich; Carlotta Povesi Dascola; Carlo Caffarelli Journal: Clin Transl Med Date: 2015-02-14